Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development
- Sci Rep. 2018 Sep 4;8(1):13191. doi: 10.1038/s41598-018-31502-6.
- 1. Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, Québec, Qc, Canada.
- 2. Division of Regenerative Medicine, CHU de Québec-Université Laval Research Center, Québec, Qc, Canada.
- 3. Department of Surgery, Faculty of Medicine, Université Laval, Québec, Qc, Canada.
- 4. Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, Québec, Qc, Canada. [email protected].
- 5. Division of Regenerative Medicine, CHU de Québec-Université Laval Research Center, Québec, Qc, Canada. [email protected].
- 6. Department of Surgery, Faculty of Medicine, Université Laval, Québec, Qc, Canada. [email protected].
While being the rarest skin Cancer, melanoma is also the deadliest. To further drug discovery and improve clinical translation, new human cell-based in vitro models are needed. Our work strives to mimic the melanoma microenvironment in vitro as an alternative to animal testing. We used the self-assembly method to produce a 3D human melanoma model exempt of exogenous biomaterial. This model is based on primary human skin cells and melanoma cell lines while including a key feature for tumor progression: blood and lymphatic capillaries. Major components of the tumor microenvironment such as capillaries, human extracellular matrix, a stratified epidermis (involucrin, filaggrin) and basement membrane (laminin 332) are recapitulated in vitro. We demonstrate the persistence of CD31+ blood and podoplanin+/LYVE-1+ lymphatic capillaries in the engineered tissue. Chronic treatment with vemurafenib was applied to the model and elicited a dose-dependent response on proliferation and Apoptosis, making it a promising tool to test new compounds in a human-like environment.
-
Cat. No.Product NameDescriptionTargetResearch Area
-